Lilly and MiNA Therapeutics Announce saRNA Research Collaboration

Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
News provided by
Share this article
MiNA Therapeutics Logo
INDIANAPOLIS and LONDON, May 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform.
Under the terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas. Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration. MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on product sales resulting from the collaboration.

Related Keywords

London ,City Of ,United Kingdom ,Andrewc Adams ,Robert Habib ,Molly Mccully ,Kevin Hern ,Sophia Hergenhan ,Eli Lilly ,Tim Stamper ,Exchange Commission ,Mina Therapeutics ,Generally Accepted Accounting Principles ,Private Securities Litigation Reform Act ,Lilly Media ,Lilly Investors ,Victoria Foster Mitchell ,Amina Media ,லண்டன் ,நகரம் ஆஃப் ,ஒன்றுபட்டது கிஂக்டம் ,ராபர்ட் ஹபீப் ,மாலீ ம்க்குள்ளி ,கெவின் ஹெர்ன் ,எலி லில்லி ,நேரம் ஸ்டாம்பர் ,பரிமாற்றம் தரகு ,மினா சிகிச்சை ,ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,லில்லி மீடியா ,லில்லி முதலீட்டாளர்கள் ,விக்டோரியா வளர்ப்பு மிட்செல் ,